Celltrion, Inc. (KRX:068270)
190,700
-600 (-0.31%)
At close: Aug 28, 2026
Celltrion Revenue
Celltrion had revenue of 1.39T KRW in the quarter ending June 30, 2026, with 44.96% growth. This brings the company's revenue in the last twelve months to 4.90T, up 30.64% year-over-year. In the year 2025, Celltrion had annual revenue of 4.16T with 17.01% growth.
Revenue (ttm)
4.90T
Revenue Growth
+30.64%
P/S Ratio
9.34
Revenue / Employee
1.83B
Employees
2,680
Market Cap
45.77T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.16T | 605.19B | 17.01% |
| Dec 31, 2024 | 3.56T | 1.38T | 63.45% |
| Dec 31, 2023 | 2.18T | -107.54B | -4.71% |
| Dec 31, 2022 | 2.28T | 390.57B | 20.63% |
| Dec 31, 2021 | 1.89T | 44.29B | 2.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.12T |
| Samsung Epis Holdings | 1.51T |
| SK Biopharmaceuticals | 861.34B |
| SK bioscience | 659.27B |
| Hugel | 479.57B |
| ALTEOGEN | 203.76B |
| LigaChem Biosciences | 125.87B |
| HLB Co., Ltd. | 97.47B |
Celltrion News
- 16 days ago - Celltrion Quarterly report: Q2 2026 - Filings
- 16 days ago - Celltrion Slides: Q2 2026 - Filings
- 2 months ago - Celltrion Q2 Operating Income Jumps - Nasdaq
- 3 months ago - Celltrion Acquires Gifrer to Expand EU Operations - GuruFocus
- 4 months ago - Celltrion Slides: Q1 2026 - Filings
- 4 months ago - Celltrion Quarterly report: Q1 2026 - Filings
- 4 months ago - Celltrion Q1 Net Income Rises - Nasdaq
- 4 months ago - Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW) - Benzinga